3.98k followers • 19 symbols Watchlist by Motif Investing
Global adoption of minimally invasive procedures could spark new growth. The global minimally invasive surgery market is forecast to reach $35.5 billion by the end of 2016 with compound annual growth rate ("CAGR") of 8.2%.
Curated by Motif Investing
A little snip can make a big difference. Patients can expect less operative trauma and faster recovery, while insurers enjoy shorter stays and lower costs. Minimally invasive surgery has become a win-win advancement that's created a $27 billion market as of 2012, up 5.4% as compared with 2010.
Many traditionally "open" surgeries that required incisions as long as 12 inches are now performed with incisions that are often no larger than the diameter of a pencil. Procedures ranging from angioplasty to laparoscopic gall bladder removal can now be done endoscopically, with robotic equipment giving doctors even greater precision and control. So scrub in. We've got work to do.
We identified US-listed stocks and American Depository Receipts of companies that are engaged in activities relevant to this watchlist's theme. We then filtered out companies that have a share price of less than $1.00 or a market capitalization less than $100 million, and excluded illiquid stocks by screening companies for liquidity i.e. average bid-ask spreads, dollar volume traded etc. Finally the proprietary Motif Optimization Engine determined the constituent stocks. Learn more about how we select our watchlists.Who made these selections?
Motif is an online brokerage built on thematic portfolios of up to 30 stocks and ETFs. Founded in 2010 by Hardeep Walia, Motif combines complex proprietary algorithms with skilled advisers to develop these thematic portfolios. Learn more about our team.How are these weighted?
First, we determined each company's percentage of total revenue derived from this watchlist's theme. Second, we applied a pure-play factor to give greater relative weight to companies that derive a higher percentage of their revenue from this theme. Finally, we weighted each company by its market capitalization adjusted for revenue exposure to the theme.
More details on how we build and weight watchlists are available here.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Minimally Invasive Surgery||-0.43%||+6.88%||-5.75%||+0.67%|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|MDT||Medtronic plc||103.495||-0.85||-0.82%||10:00 am GMT-4||380.64k||4.81M||139.12B|
|ISRG||Intuitive Surgical, Inc.||667.124||+1.10||+0.17%||10:00 am GMT-4||91.09k||632.13k||78.07B|
|BSX||Boston Scientific Corporation||38.27||-0.33||-0.85%||10:00 am GMT-4||387.05k||8.57M||54.75B|
|SNN||Smith & Nephew plc||38.385||+0.66||+1.76%||10:00 am GMT-4||32.79k||415.47k||16.76B|
|HOLX||Hologic, Inc.||64.66||-0.72||-1.10%||10:00 am GMT-4||90.35k||2.44M||16.75B|
|NTRA||Natera, Inc.||64.01||-||-||10:00 am GMT-4||46.08k||784.81k||5.38B|
|GMED||Globus Medical, Inc.||49.87||-0.40||-0.80%||9:59 am GMT-4||75.15k||864.50k||4.88B|
|NUVA||NuVasive, Inc.||50.88||-0.15||-0.29%||9:59 am GMT-4||13.57k||809.88k||2.61B|
|CNMD||CONMED Corporation||75.27||-0.26||-0.34%||9:58 am GMT-4||7.78k||281.01k||2.15B|
|GKOS||Glaukos Corporation||47.18||-1.03||-2.14%||9:59 am GMT-4||10.92k||581.15k||2.11B|
|CSII||Cardiovascular Systems, Inc.||35.63||+0.44||+1.25%||10:00 am GMT-4||13.90k||355.27k||1.41B|
|ANGO||AngioDynamics, Inc.||10.01||-0.11||-1.09%||9:59 am GMT-4||22.09k||264.62k||379.11M|
|ARAY||Accuray Incorporated||2.39||-0.03||-1.24%||10:00 am GMT-4||52.94k||610.75k||217.96M|
|ELGX||Endologix, Inc.||0.22||-0.07||-23.88%||4:00 pm GMT-4||7.80M||2.06M||4.22M|
|SPNC||-||-||-||-||6:07 pm GMT-4||-||-||-|
|KTWO||K2M Group Holdings, Inc.||-||-||-||6:07 pm GMT-4||-||-||-|
|CYNO||-||-||-||-||6:07 pm GMT-4||-||-||-|
|ALOG||Analogic Corporation||-||-||-||6:07 pm GMT-4||-||-||-|
|MZOR||Mazor Robotics Ltd.||-||-||-||6:07 pm GMT-4||-||-||-|
These great companies offer a blend of growth, income, and capital preservation that mature investors are bound to appreciate.
The medical device company has been consistently building revenue and has an established foothold in robotic surgery.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first enrollments in the ALLEVIATE-HF clinical trial which will evaluate the ability of its Reveal LINQ™ Insertable Cardiac Monitor (ICM) in identifying patients at high-risk of worsening heart failure. The trial will determine if early information provided by the LINQ devices enable clinicians to take action before patients' conditions worsen. The LINQ device will alert clinicians if a patient is at high risk for a heart failure event, allowing time for a physician to adjust medications to enhance patient health.